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Objective: Cardiopulmonary bypass triggers a systemic inflammatory response that
alters pulmonary endothelial function, which can contribute to pulmonary hyper-
tension. This study was designed to demonstrate that inhaled prostacyclin, a selec-
tive pulmonary vasodilator prostaglandin, prevents pulmonary arterial endothelial
dysfunction induced by cardiopulmonary bypass.
Methods: Three groups of Landrace swine were compared: control without cardio-
pulmonary bypass (control group); 90 minutes of normothermic cardiopulmonary
bypass (bypass group); 90 minutes of cardiopulmonary bypass and treated with
prostacyclin during cardiopulmonary bypass (continuous nebulization with contin-
uous positive airway pressure until the end of the cardiopulmonary bypass; prosta-
cyclin group). After 60 minutes of reperfusion, swine were put to death and
pulmonary arteries harvested. After contraction to phenylephrine, endothelium-
dependent relaxation to bradykinin and acetylcholine was studied in standard organ
chamber experiments. The pulmonary artery intravascular cyclic adenosine mono-
phosphate content was compared between the 3 groups (post–cardiopulmonary
bypass).
Results: There was a statistically significant improvement of the endothelium-
dependent relaxation to bradykinin in the prostacyclin group when compared with
the bypass group (P  .05). There was no statistically significant difference for
endothelium-dependent relaxation to acetylcholine (P  .05) between the prosta-
cyclin and the bypass groups. There was a statistically significant decrease in the
cyclic adenosine monophosphate content and a statistically significant increase of
the mean pulmonary artery pressure in the bypass group only (P  .05).
Conclusion: Prophylactic use of inhaled prostacyclin has a favorable impact on the
pulmonary endothelial dysfunction induced by cardiopulmonary bypass associated
with preservation of pulmonary intravascular cyclic adenosine monophosphate
content and the pulmonary vascular tone.
Postpump syndrome was identified early following the development ofcardiopulmonary bypass (CPB) in the 1950s and is characterized byincreased alveolo-arterial gradient (A-aDO2) and intrapulmonaryshunt, decreased pulmonary compliance, and increased pulmonaryvascular resistance and permeability1,2 and is related to the systemicinflammatory response associated with CPB.3 Ischemia-reperfusion
injury is the major cause of this syndrome but contact of blood with the nonphysi-
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ological surface of the circuit and endotoxemia are also
implicated in a cascade of events including activation of the
complement system, induction of adhesion molecules, cy-
tokine release, and neutrophil activation. The final pathway
of this inflammatory process leads to activation and dys-
function of the endothelium.3,4
Pulmonary endothelium, presenting a total surface area
of 200 m2 in adults, is in constant interaction with the blood
elements.5 Beyond its roles as selective barrier, the endo-
thelium allows inhibition of platelet aggregation and neu-
trophil adhesion and elaborates powerful vasoactive sub-
stances that control blood flow and vascular remodeling.
Appropriate endothelial function results from the equilib-
rium between endothelium-dependent relaxing factors
(EDRF), such as nitric oxide (NO) and prostacyclin, and
endothelium-dependent contracting factors (EDCF), such as
endothelin. Endothelial dysfunction can be defined as an
imbalance between relaxing factors and contracting factors
and results in the loss of the normal protective role of the
endothelium in the homeostasis of the vascular wall.6 In
vascular reactivity studies, only the vasomotor control func-
tion of the endothelium is studied.
Prostacyclin (PGI2) is an endogenous prostaglandin de-
rived from arachidonic acid metabolism through the cyclo-
oxygenase pathway in the vascular endothelium. PGI2 binds
to a Gs-protein–related receptor, which when activated in-
creases cyclic adenosine monophosphate (cAMP) concen-
tration, activating a protein kinase A to decrease free intra-
cellular calcium concentration (Figure 1). The physiological
effects are vascular dilatation (predominantly in resistance
vessels), inhibition of endothelin secretion, inhibition of
platelet aggregation, and inhibition of leukocyte adhesion to
the endothelium.7
In the cardiac surgery setting, PGI2 has been used in
clinical situations such as pulmonary hypertension and the
adult respiratory distress syndrome following CPB.7,8 Intra-
venous infusion of PGI2 may increase intrapulmonary shunt
and cause systemic vasodilatation that can be deleterious in
hemodynamically unstable patients.7 Due to these systemic
side effects, researchers have favored the bronchial tree as a
route of administration9 because the aerosolized form of
PGI2 causes a selective dilatation of the pulmonary vessels
and improves right ventricular (RV) function and the car-
diac output without systemic hypotension encountered with
the intravenous administration.
A selective endothelial dysfunction of the pulmonary
arterial tree involving relaxation mediated by muscarinic
receptors to acetylcholine (Gi-coupled) following CPB in a
porcine model was demonstrated in our laboratory.10 The
aim of this experimental study in a porcine model was first
to determine the effect of prophylactic use of inhaled PGI2
before CPB on the pulmonary endothelial function and
second to examine its effect on hemodynamic data, on the
A-aDO2, and on pulmonary artery pressures.
Materials and Methods
Experimental Surgery/Anesthesia (General
Preparation)
All experiments were performed using white Landrace swine
(McGill University, Montreal, Quebec, Canada) of either gender,
aged 8  1 weeks and weighing 29.8  2.2 kg. Animals were
maintained and tested in accordance with the recommendations of
the Guidelines on the Care and Use of Laboratory Animals issued
by the Canadian Council on Animals and approved by a local
ethics committee. Induction was achieved using mask ventilation
with 2% isoflurane (Abbott Laboratories, Limited, St Laurent,
Quebec, Canada). They were subsequently intubated and mechan-
Figure 1. PGI2 was administered through an in-line nebulizer
connected to the inspiratory limb of the ventilator. A CPAP was
used during CPB to distribute the drug to the lungs. A summary of
the endothelial transduction signal pathways for NO (through ACh
and BK) and for PGI2 is shown. See text for more details.
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ically ventilated with a constant oxygen/air mixture (3:2, FIO2
68%) at 14 breaths/min and tidal volume of 6 to 8 mL/kg. Anes-
thesia was maintained with 1% isoflurane inhalation. Following
skin preparation and draping with sterile field, a Swan-Ganz cath-
eter (Edwards Lifesciences, Irving, Calif) was inserted through the
jugular vein to measure pulmonary artery pressure. Arterial and
venous blood gases were measured at regular intervals during the
experiment and maintained within physiological limits (pH 7.35-
7.45 and PaCO2 35-45 mm Hg) by adjusting ventilation rate and
tidal volume. The electrocardiogram was recorded from 3 subcu-
taneous limb electrodes.
Experimental Groups
Group 1: Control (n  6). The mediastinum was exposed via
a median sternotomy. Heparin (300 UI/kg; Leo Pharma, Inc, Ajax,
Ontario, Canada) was given intravenously. After 1 hour of general
anesthesia with 1% isoflurane, the animal was exsanguinated and
the heart and lung harvested.
To study the effect of these drugs on pulmonary vascular
reactivity, a preliminary experiment was conducted. Four animals
underwent median sternotomy. After 1 hour of general anesthesia
with 1% isoflurane, anesthesia was changed to propofol for 1.5
hours (0.1-0.2 mg/kg/min, same dosage as in the CPB groups),
followed by 1 hour with 1% isoflurane to match the time and drugs
used in the other groups. Arterial pressure was maintained with
crystalloid (Ringer’s lactate). The animal was then exsanguinated
and the lungs harvested. Endothelium-dependent relaxation to
bradykinin (BK) and acetylcholine (ACh) was comparable to the
control group used in the study (data not shown). These organ
chamber experiments confirmed that normal animals could be used
as parallel control animals.
Group 2: Cardiopulmonary Bypass (n  6). After sternot-
omy, the aorta and right atrium were cannulated following heparin
administration (300 UI/kg), when activated coagulation time
(ACT, assessed with Hemochron 801; Technidyne, Edison, NJ)
was superior to 300 seconds. CPB was initiated when ACT was
superior to 400 seconds. Ventilation and isoflurane were stopped
but a continuous positive airway pressure (CPAP) of 3 cm H2O
was maintained throughout the CPB period. Anesthesia was main-
tained with a continuous infusion of propofol (0.1-0.2 mg/kg/min).
The pump flow was adjusted to obtain an index of 2.4 L/min/m2
and assessed by venous gases to maintain mixed venous saturation
over 60%. FIO2 was kept constant at a level of 68%. Mean systemic
arterial pressure was maintained between 50 and 70 mm Hg with
crystalloid (Ringer’s lactate). The temperature was allowed to drift
to 36°C. The heart was left beating, empty. No aortic crossclamp-
ing or cardioplegic solution was used. Before CPB weaning, swine
were rewarmed to 38°C (normal porcine temperature). After 90
minutes of CPB, mechanical ventilation and isoflurane anesthesia
were reinstituted and CPB was weaned. No protamine was given
due to its potential cardiovascular effects such as complement
activation and NO production.11 Normal circulation was restored
for 60 minutes, at which time the animal was exsanguinated into
the cardiotomy reservoir. The beating heart and the lungs were
excised “en bloc” and immediately immersed in a cold modified
Krebs–bicarbonate solution (composition in mmol/L: NaCl 118.3,
KCl 4.7, MgSO4 1.2, KH2PO4 1.2, glucose 11.1, CaCl2 2.5,
NaHCO3 25, and ethylenediaminotetraacetic acid 0.026).
Group 3: Cardiopulmonary Bypass and Inhaled Prostacyclin
(n  5). The same procedure was followed as in the CPB group
(group 2). The only difference was that a bolus of 2 to 2.5 g/kg
of PGI2 was given via the endotracheal tube through a nebulizer
during the 30 minutes preceding the initiation of CPB (Figure 1).
Ventilation was then stopped but a continuous nebulization of
PGI2 at a rate of 0.1 g/kg/min with CPAP of 3 cm H2O was then
instituted until the end of the CPB. Before weaning of CPB,
nebulization was stopped and ventilation reinstituted. The dosages
were based on review of the literature7 and our experience with
this medication.8,12
PGI2 (Flolan, Glaxo Wellcome, Mississauga, Ontario, Canada)
was given as epoprostenol salt 1.5 mg dissolved in 100 mL of
sterile glycine buffer diluent for a concentration of 15 g/mL. The
drug was administered through a conventional in-line nebulizer kit
(Salter Labs, Arvin, Calif) connected to the inspiratory limb of the
ventilator.
Hemodynamic and Biochemical Data
Arterial and venous blood gases were measured at regular intervals
during the experiment (baseline, during CPB, immediately after
weaning from CPB, and at death) Pulmonary artery pressures were
measured with a Swan-Ganz catheter at different intervals during
the procedure: after induction, before CPB, and after weaning of
CPB (0 minute, 10 minutes, 15 minutes, 45 minutes, and 60
minutes).
Vascular Reactivity Studies
Less than 10 minutes after en bloc excision, the heart was removed
and the primary pulmonary artery was dissected. Branches of
second-degree pulmonary arteries were isolated and dissected free
of connective and adventitial tissue and divided into rings (4 mm
wide; 16 rings per animal). All rings were placed in organ cham-
bers (Emka Technologies Inc, Paris, France) filled with 20 mL
modified Krebs–bicarbonate solution continuously heated at 37°C
and oxygenated with a carbogen mixture (95% O2 and 5% CO2).
The rings were suspended between 2 metal stirrups with the upper
1 connected to an isometric force transducer connected to a signal
amplifier and then allowed to stabilize for 30 minutes. Data were
collected with a biological signal data acquisition software (IOX
1.203; Emka Technologies Inc). Each arterial ring was stretched to
the optimal point of its active length-tension curve (3.5 g) as
determined by measuring the contraction to potassium chloride
(KCl) 60 mmol/L at different levels of stretch (data not shown).
The maximal contraction of rings was then obtained with addition
of potassium chloride (KCl 60 mmol/L). After obtainment of a
plateau, all baths were washed twice with modified Krebs–bicar-
bonate solution and indomethacin (105 mmol/L; to exclude pro-
duction of endogenous prostanoids) was added in each bath. After
60 minutes of stabilization, phenylephrine (PE; range 2  107
mol/L to 3  106 mol/L) was added to obtain a contraction
averaging 50% of the maximal contraction to KCl.
Endothelium-Dependent Relaxation. The NO-mediated re-
laxation pathway was studied by constructing concentration-re-
sponse curves to ACh (1010 to 105 mol/L; an agonist of M2
receptors coupled to Gi-proteins) and to (1012 to 106 mol/L; an
agonist of B2 receptors coupled to Gq-proteins).
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Endothelium-Independent Relaxation. At the end of the ex-
periment, endothelium-independent relaxation was studied with
the use of 105 mol/L sodium nitroprusside (SNP), a nitric oxide
donor.
Drugs
All drugs were prepared daily. ACh, BK, indomethacin, and so-
dium SNP were obtained from Sigma Chemical Co (Oakville,
Ontario, Canada). Phenylephrine was obtained from Cayman
Chemical Company (Ann Arbor, Mich).
Determination of Pulmonary Artery Intravascular
cAMP Content
To determine the vascular content of porcine pulmonary arteries,
rings from the 3 groups were collected after death, frozen in liquid
nitrogen, and stored at 70°C. At the time of analysis, all seg-
ments were pulverized in a liquid nitrogen–cooled stainless steel
mortar, and then transferred in trichloracetic acid solution (6.25%
w/v). The acid extracts were then centrifuged at 4°C for 15 minutes
at 12,000g (3000 revolutions per minute) to precipitate cell debris
and proteins. The pellets were used for total protein determination
using the Bradford microassay technique (Bio-Rad, Mississauga,
Ontario, Canada). To remove trichloracetic acid, the supernatants
were extracted 4 times with water-saturated diethyl ether. Any
residual diethyl ether was removed by heating the samples to 90°C
for 3 to 5 minutes. cAMP quantification was done using an enzyme
immunoassay system with acetylation based on rabbit anti-cAMP
antibody (Amersham Pharmacia Biotech, Baie d’Urfe´, Quebec,
Canada). The amount of cAMP in each blood vessel ring was
standardized to pmol cAMP  mg1 protein.
Total Antioxidant Plasma Status
The assay antioxidant levels in plasma samples rely on the ability
of antioxidants in the sample to inhibit the oxidation of ABTS
(2,2'-Azino-di-[3-ethylbenzthiazoline sulphonate]) to ABTS by
metmyoglobin (a peroxidase). The amount of ABTS produced
can be monitored by reading the absorbance at 600 nm. Under the
reaction conditions used, the antioxidants in the sample cause
suppression of the absorbance at 600 nm to a degree that is
proportional to their concentration. Blood samples from groups
were drawn from right atrium before and after CPB in ethylenedia-
minetetraacetic acid to prevent coagulation and subsequently were
centrifuged. The isolated plasma was then frozen and kept at
70°C until analysis. The plasma samples were analyzed with
Total Antioxidant status activity Assay Kit (Calbiochem, San
Diego, Calif). The concentration of ABTS were measured with a
spectrophotometer set at 600 nm.
Statistical Analysis
All values are expressed as the mean  standard error of the mean
(SEM). Contractions to PE are expressed as a percentage of the
maximal contraction to KCl (60 mmol/L). Relaxations are ex-
pressed as the percentage of the maximal contraction to PE for
each ring. Two-way analyses of variance (ANOVA) were per-
formed with 1 repeated measure (ACh and BK doses) to compare
the concentration-response curves between the 3 groups, followed
by pairwise comparisons when the global ANOVA was significant.
One-way ANOVA was performed to compare groups for contrac-
tions and cAMP. Two-way ANOVA was performed with 1 re-
peated measure (time) to compare the hemodynamic data (mean
arterial pressure [mAP], mean pulmonary artery pressure [mPAP],
pulmonary vascular resistance index [PVRI], SvO2, A-aDO2, lac-
tic acid levels), followed by pairwise comparisons when the global
ANOVA was significant. Statistical analysis was performed with
the computer software SAS (SAS Institute, Inc, Cary, NC).
Results
Hemodynamic and Biochemical Data
Following CPB, there was a statistically significant eleva-
tion of the mPAP at 0 and 10 minutes (P  .05; Figure 2).
In the group treated with PGI2, this elevation was not
observed and the mPAP was more constant. There was a
statistically significant increase of the A-aDO2 after CPB in
the group without PGI2 (P  .05), but not in the group with
PGI2 (Table 1).
Lactic acid levels were elevated after CPB in both
groups. The SvO2 level was decreased in both CPB groups
after CPB. There was no statistically significant difference
in lactic acid and SvO2 levels after CPB between the 2
groups. There was no statistically significant difference in
the mAP, the pH, and the PVRI (P  .05; Table 1). There
was no statistically significant difference in the mAP before
and during PGI2 nebulization (66  6 vs 65  5; P  .05).
Vascular Reactivity Study
Contractions. The amplitude of the contraction to KCl
(60 mmol/L) and to PE and the concentration of PE used
were quantified for both groups in Table 2. The amplitude of
contraction to KCl (endothelium-independent agent) was
significantly lower in the control group and higher in the
CPB group without PGI2. Conversely, there was no differ-
ence in contraction to PE (endothelium-dependent agent)
between the 2 CPB groups, but the CPB group without PGI2
required a significantly higher PE concentration to achieve
the same level of contraction (P  .05).
Figure 2. Mean pulmonary artery pressures (mPAP) with and
without PGI2 before, during, and after CPB. *P < .05 post-CPB
versus pre-CPB (group without PGI2 only).
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Endothelium-Dependent Relaxation. There was a sta-
tistically significant decrease of endothelium-dependent re-
laxation to ACh in both CPB groups when compared with
controls (P  .05; Figure 3,A). However, there was no
statistically significant difference between the CPB group
with PGI2 and the CPB group without PGI2 (P  .05).
There was a statistically significant decrease in endothe-
lium-dependent relaxation to BK in the CPB group without
PGI2 when compared with the control group (P  .05) and
a greater maximal relaxation to BK in the group with PGI2
when compared with the CPB group (P  .05; Figure 3, B).
There was no statistically significant difference between the
PGI2 and the control groups (P  .05).
Endothelium-Independent Relaxation. No statistically
significant difference in relaxation to the SNP was observed
between groups, with all rings achieving 100% relaxation
(data not shown).
Influence of Indomethacin
In some baths, indomethacin was not added in order to
eliminate its influence on PGI2. No statistically significant
difference in contraction to KCl or PE or relaxation to ACh
or BK was demonstrated in baths with and without indo-
methacin between the 3 groups (data not shown).
Pulmonary Artery Intravascular cAMP Content
There was a statistically significant lower cAMP content in
the vascular rings of the CPB group without PGI2 when
compared with the controls and with the CPB group with
PGI2 (P  .05; Figure 4).
Total Antioxidant Plasma Status
There was no statistically significant difference in the total
antioxidant plasma status between both CPB groups (CPB
0.55 mmol/L  0.10 pre-CPB and 0.62 mmol/L  0.08
post-CPB; PGI2 0.61 mmol/L  0.05 pre-CPB and 0.56
mmol/L  0.03 post-CPB; P  .05).
Discussion
The aim of the present study was to document the effect of
prophylactic use of inhaled PGI2 during CPB. The major
findings are the following: (1) inhaled PGI2 prevents the
increase of the mPAP following CPB; (2) PGI2 is associated
with a lower increase of the A-aDO2; (3) animals receiving
PGI2 had a maximal response of the pulmonary endotheli-
um-dependent relaxation involving receptors coupled to
Gq-proteins but no change in the pathway involving recep-
tors coupled to Gi-proteins; and (4) the administration of
PGI2 is associated with preservation of pulmonary arterial
cAMP content after CPB.
Congenital and adult heart surgery such as mitral valve
replacement are commonly followed by pulmonary hyper-
tension in the postoperative period.13 CPB can directly
cause pulmonary vascular injury. Endothelial dysfunction
may leave the pulmonary adrenergic system unopposed,
with an increase in vascular tone, which can result in RV
failure and low output syndrome.13 Morita and colleagues14
demonstrated in a porcine model that CPB causes a signif-
icant increase in pulmonary vascular resistance and de-
presses the RV function by more than 50%. Several studies
have demonstrated that RV dysfunction is a negative prog-
nostic factor after cardiac surgery. Perioperative mortality
ranges from 44% to 86% in patients with RV dysfunction.15
Furthermore, RV systolic dysfunction has been shown to be
associated with poor outcome in patients undergoing myo-
cardial revascularization with reduced left ventricular func-
tion.16 After CPB, pulmonary hypertension can be pre-
vented by avoidance of hypoxia, hypercarbia, acidosis, and
hypothermia as well as optimization of airway pressures and
depth of anesthesia.13
Numerous experimental and human studies have demon-
strated elevation of PGI2 levels during CPB with return to
the baseline level immediately following CPB.17 As the
relative decrease of PGI2 following CPB may explain the
rise in pulmonary artery pressure, our main hypothesis was
TABLE 2. Contraction to KCl (60 mmol/L) and PE of porcine
pulmonary arteries after CPB with or without PGI2
Group
Control
(n  6)
CPB
(n  6)
PGI2
(n  5)
KCl (60 mmol/L) (g) 5.1 0.3†‡ 7.5 0.4§ 6.1 0.3
PE (g) 3.0 0.2†‡ 4.1 0.3 4.5 1.7
% PE/KCl 61 1†‡ 55 2§ 76 2
Dosage of PE (107 mol/L)* 5.5 0.9† 18.8 1.7§ 6.5 0.6
KCl, potassium chloride; PE, phenylephrine; CPB, cardiopulmonary bypass;
PGI2, prostacyclin. Data are shown as mean  SEM.
*For achieving target level of contraction.
†P  .05 control versus CPB.
‡P  .05 control versus PGI2.
§P  .05 CPB versus PGI2.
TABLE 1. Hemodynamic and respiratory data of swine
after CPB with or without PGI2
mAP mPAP PVRI LA SvO2 A-aDO2
Baseline
CPB 73 5 12 3 150 31 2.6 0.2 69 2 188 23
PGI2 66 6 16 2 151 22 3.1 0.6 77 2 171 33
Post-CPB
CPB 73 5 23 3* 179 31 5.2 0.6* 53 2* 265 32*
PGI2 67 1118 2 171 12 6.4 1.8* 61 8* 210 16
mAP, Mean arterial pressure (mm Hg); mPAP, mean pulmonary artery
pressure (mm Hg); PVRI, pulmonary vascular resistance index (dynes sec
m2/cm5); LA, lactic acid (mmol/L); SvO2, venous saturation in O2 (%);
A-aDO2, alveolo-arterial gradient (mm Hg); CPB, cardiopulmonary bypass;
PGI2, prostacyclin. Data are shown as means  SEM.
*P  .05 pre- versus post-CPB.
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that PGI2 loading before CPB could prevent the pulmonary
artery pressure elevation and secondary RV dysfunction.
In humans, pulmonary hypertension is defined as an
mPAP of more than 25 mm Hg but no such definition exists
in swine. The results of the present study demonstrate that
administration of inhaled PGI2 before CPB effectively at-
tenuates pulmonary artery pressure elevation secondary to
CPB. Also, the adverse systemic effects of inhaled PGI2 on
oxygen exchange are minimal due to its pulmonary selec-
tivity,8 as shown by the absence of hypotension and pres-
ervation of the A-aDO2 in the PGI2 group compared with
the CPB only group. The inhaled route of delivery is most
likely responsible for the improvement in A-a gradient in
this model.
Contraction to KCl is a receptor-independent response of
vascular smooth cells. Contractions with KCl were greater
in the CPB group without PGI2. However, a higher concen-
tration of PE was necessary to achieve the same level of
contraction in the aforementioned group than in the CPB
group with PGI2, which can be explained by a decreased
number of pulmonary -receptors or reduced sensitivity of
these receptors. In humans, CPB is associated with an
impairment of -adrenergic responsiveness, apparently due
to desensitization of -receptors.18 This may be due to the
influence of hemodilution, hypothermia, alteration of drug
pharmacokinetics, or increased level of plasmatic cat-
echolamines.18 One explanation for the better -adrenergic
responsiveness in the PGI2 group comes from the findings
from Wachtogel and colleagues.19 The loss of platelet -ad-
renergic receptors during extracorporeal circulation is pre-
vented with prostaglandin E1 (PGE1),19 a vasodilator pros-
taglandin similar in structure and effects to PGI2.17
A decreased pulmonary production of NO after CPB has
been demonstrated in numerous studies.14,20 ACh induces a
Figure 3. Cumulative concentration-response curves to (A) acetylcholine (ACh) and to (B) bradykinin (BK) in rings
of porcine pulmonary arteries with endothelium. Results are presented as the means  SEM. The asterisks
indicate statistically significant difference between both CPB groups and control (*), between control and CPB
groups (**), and between CPB and PGI2 groups (***) (P < .05).
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dose-dependent vasomotor effect dependent on the preex-
isting vascular tone. Under resting conditions, ACh induces
vasoconstriction and vasodilatation under conditions of el-
evated tone.21 ACh-related NO pathway appears to be pref-
erentially damaged.10,22 Indeed, Gagnon and colleagues10
have shown in a porcine model that CPB with reperfusion of
the pulmonary tree induces a decrease in endothelium-
dependent relaxation mediated by muscarinic receptors,
which was also demonstrated in a dog model by Zanaboni
and colleagues.22 Although ACh induces endothelium-de-
pendent relaxation through both the NO and cAMP path-
ways,23 more specific signal transduction pathways alter-
ations may explain the lack of benefit of inhaled PGI2 in
ACh-induced dysfunction in this study.
BK is an agonist that binds to B2 receptors coupled to
Gq-proteins, which causes release of NO in pulmonary
endothelium but also stimulates prostacyclin release,21 re-
sulting in vasodilatation independently of the preexisting
vascular tone. This study demonstrates complete relaxation
of the pulmonary rings with BK after PGI2 administration,
which can be attributed to this prostacyclin stimulation.
This interaction between cAMP and NO has been recently
studied in canine coronary arteries in which activation of the
cAMP signal transduction increases endothelial NO produc-
tion.24
PGI2 binds to Gs-protein receptors and induces an in-
crease in cAMP concentration. In this study, CPB causes a
significant decrease in cAMP content. However, adminis-
tration of inhaled PGI2 before CPB increases these levels
and prevents its subsequent decrease. These data indicate
that cAMP signal transduction may be an important poten-
tial compensatory pathway to the dysfunctional NO path-
way.
The CPB-induced systemic inflammatory response con-
tributes to the release of reactive oxygen species (ROS),
which may in part explain the vasoconstriction following
weaning of CPB due to scavenging of NO by ROS.7 PGI2
has cytoprotective effects due to its ability to scavenge the
ROS and reduces the synthesis of proinflammatory cyto-
kines such as tumor necrosis factor .7 In the current study,
the antioxidant activity was measured from the right atrium
instead of lung tissue or left atrium plasma, which may
explain in part the lack of difference between the CPB and
the PGI2 groups.
Clinical Implications
Congenital heart disease and pretransplantation status are
frequently associated with a preexisting pulmonary hyper-
tension. Inhaled PGI2 has been used to evaluate the revers-
ibility of pulmonary hypertension of potential candidates for
heart transplantation.25 To our knowledge, no study has
examined the role of pre-CPB use of vasodilators such as
PGI2 and NO to prevent post-CPB pulmonary hypertension.
The inhaled form is especially effective due to pulmonary
selectivity and prevention of hypotension, which could be
deleterious in high-risk patients.
Limitations
The amount of inhaled PGI2 reaching the alveoli cannot be
precisely determined due to drug deposition in the ventilator
and orotracheal tubing. Data have demonstrated that there is
less than 10% of alveolar deposition of drug during me-
chanical ventilation.26 However, the PGI2 concentration use
in our study was comparable to other published studies12,26
with evident hemodynamic results. There was no inhalation
of a placebo in the CPB group, so we cannot exclude a
possible interference of CPAP on our results and the inhaled
route of delivery may be responsible for the improvement in
the A-a gradient. However, it has been previously demon-
strated that a CPAP of 5 cm H2O does not prevent the
post-CPB lung function impairment.27 Also, the PGI2 group
has not been compared with an inhaled glycine group, the
Figure 4. Pulmonary artery intravascular cAMP content in the control group and the CPB group following death.
Results are presented as the mean  SEM. The asterisks (*) indicate statistically significant difference between
the CPB group and the control and PGI2 groups (P < .05).
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buffer vehicle used to transport PGI2 molecules. However,
glycine has no hemodynamic and respiratory parameter
influence and is not associated with major signs of acute
pulmonary toxicity.28,29 Use of healthy swine in this study
instead of a model with pre-CPB pulmonary hypertension
could have minimized our results. Finally, a species speci-
ficity of swine intravascular macrophages cannot be ex-
cluded, which could limit the clinical relevance of the
present study.
Conclusion
CPB causes an increase in pulmonary vascular resistance,
which may induce RV dysfunction. Also, the inflammatory
response associated with CPB impairs endothelium-depen-
dent relaxation, which can further contribute to pulmonary
hypertension. Administration of inhaled PGI2 during CPB
improves the endothelial dysfunction via an increase of the
cAMP content of pulmonary arteries and partially compen-
sates for the decrease in endothelial production of NO.
Inhaled PGI2 also stabilizes the mPAP and maintains the
oxygen exchanges (A-aDO2). Clinical studies should be
undertaken to determine the impact of inhaled PGI2 on
post-CPB hemodynamic and lung function.
We thank Sylvie Le´vesque of the Department of Biostatistics of
the Montreal Heart Institute for the statistical work and France
The´riault for the preparation of the manuscript.
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